HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Beijing Airdoc Technology (2251.HK) - Here Are the Concerns

Shanghai Junshi Bioscience (1877.HK/688180.CH) - Behind the “break Up” with AstraZeneca

Pre-IPO Betta Pharmaceuticals - Lack of Staying Power

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Shenzhen Chipscreen Bioscience / Equity Bottom-Up

Shenzhen Chipscreen Bioscience (688321 CH)

<ul>
<li>The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain. </li>
<li>The continuous large investment in R&amp;D, high selling expenses, and declining R&amp;D expending capitalization would further drag down profitability.</li>
<li>So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.</li>
</ul>


The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain. 
The continuous large investment in R&amp;D, high selling expenses, and declining R&amp;D expending capitalization would further drag down profitability.
So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.


Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities